A multidistrict antitrust litigation over the generic drugs Digoxin and Doxycycline has been significantly expanded to include numerous additional class action cases, all stemming from a wide-ranging federal probe that last year led two pharmaceutical executives to plead guilty to price-fixing charges.

The U.S. Judicial Panel on Multidistrict Litigation issued an order April 7 transferring several cases into the MDL that is pending in the U.S. District Court for the Eastern District of Pennsylvania with Judge Cynthia Rufe presiding.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]